Stockscreener 앱 받기
3.27
1.55%
0.05
시간 외 거래:
3.27
전일 마감가:
$3.22
열려 있는:
$3.22
하루 거래량:
305.58K
Relative Volume:
0.49
시가총액:
$201.49M
수익:
$40.37M
순이익/손실:
$-119.72M
주가수익비율:
-1.6028
EPS:
-2.0402
순현금흐름:
$-135.06M
1주 성능:
+0.00%
1개월 성능:
+3.48%
6개월 성능:
-3.54%
1년 성능:
-12.10%
1일 변동 폭
$3.135
$3.29
1주일 범위
$3.135
$3.33
52주 변동 폭
$2.935
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
명칭
Voyager Therapeutics Inc
전화
857-259-5340
주소
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.27 | 197.18M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-02 | 개시 | Citigroup | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-10-16 | 개시 | Leerink Partners | Outperform |
| 2024-03-26 | 개시 | Guggenheim | Buy |
| 2024-03-19 | 개시 | H.C. Wainwright | Buy |
| 2024-03-07 | 개시 | Citigroup | Buy |
| 2024-01-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | 개시 | Truist | Buy |
| 2023-03-10 | 개시 | Oppenheimer | Outperform |
| 2021-10-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-02-03 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-24 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-11-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | 개시 | The Benchmark Company | Buy |
| 2020-02-06 | 개시 | Oppenheimer | Outperform |
| 2018-11-15 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-09-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | 개시 | H.C. Wainwright | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-02-02 | 개시 | Morgan Stanley | Overweight |
| 2017-11-28 | 재개 | Piper Jaffray | Overweight |
| 2017-10-31 | 개시 | Robert W. Baird | Outperform |
| 2017-10-27 | 개시 | Canaccord Genuity | Buy |
| 2017-10-23 | 재확인 | Stifel | Buy |
| 2017-10-12 | 개시 | Raymond James | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-28 | 재개 | Stifel | Buy |
모두보기
Voyager Therapeutics Inc 주식(VYGR)의 최신 뉴스
Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - stocktitan.net
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Moomoo
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus
Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Voyager Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Voyager Reports Second Quarter 2026 Financial and Operating Results - The Manila Times
Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028 - TradingView
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows - TradingView
Voyager Therapeutics (Nasdaq: VYGR) gains FDA IND clearance for VY1706 - Stock Titan
VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION - Moomoo
Voyager Therapeutics (VYGR) Edges Higher by 1.45% as Shares Defend $2.99 SupportFibonacci Arc - dars.gov.et
Voyager Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR): Millennium entities disclose 7.4% beneficial stake in Schedule 13G/A - stocktitan.net
Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday - MarketBeat
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VYGR|Voyager Therapeutics Inc|Price:3.090|Chg%:-0.010 - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Cash Flow - TradingKey
TradingKey - TradingKey
Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR - TradingView
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data - Investing.com Nigeria
Voyager Therapeutics (VYGR) Dips 3.79% as Shares Test Support Near $3.0Max Pain Level - dars.gov.et
Voyager’s gene therapy reduces tau levels in AD models - BioWorld News
Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - Sahm
Voyager Therapeutics advances tau-silencing gene therapy program - TipRanks
Voyager reports VY1706 Alzheimer’s therapy data - grafa.com
Voyager Therapeutics Presents Positive GLP Toxicology Data for VY1706 Tau Silencing Gene Therapy in Alzheimer’s Disease, Plans Clinical Trial in 2026 – Minichart - Minichart
Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus
Voyager presents six-month data for Alzheimer’s gene therapy By Investing.com - Investing.com Nigeria
[8-K] Voyager Therapeutics, Inc. Reports Material Event - Stock Titan
Voyager presents six-month data for Alzheimer’s gene therapy - Investing.com
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 - GlobeNewswire
Single-dose Alzheimer’s gene therapy from Voyager lowers brain tau in primates - stocktitan.net
Voyager Therapeutics (VYGR) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Voyager Therapeutics Inc (VYGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):